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There is a large number of effective cytotoxic drugs whose side effect profile, efficacy, and long-term use in man 
are well understood and documented over decades of use in clinical routine e.g. in the treatment of recurrent 
glioblastoma multiforme (GBM) and the hormone-refractory prostate cancer (HRPC). Both cancers are insensitive 
against most chemotherapeutic interventions; they have low response rates and poor prognoses. Some cytotoxic 
agents can be significantly improved by using modern technology of drug delivery or formulation. We succeeded 
to enhance the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly 
efficient chemotherapeutic temozolomide (TMZ) as an example. The TMZ connection to transporter molecules 
(TMZ-BioShuttle) resulted in a much higher pharmacological effect in glioma cell lines while using reduced 
doses. This permits the conclusion that a suitable chemistry could realize the ligation of pharmacologically active, 
but sensitive and highly unstable pharmaceutical ingredients without functional deprivation. The re-formulation 
of TMZ to TMZ-BioShuttle achieved a nearly 10-fold potential of the established pharmaceutic TMZ far beyond 
the treatment of brain tumors cells and results in an attractive reformulated drug with enhanced therapeutic in-
dex. 
Key words: BioShuttle, Carrier Molecules; Drug Delivery; facilitated Transport; Glioblastoma multiforme (GBM); Reformula-
tion, Temozolomide (TMZ) 
Introduction 
The medicinal treasures in the pharmacopoeia 
worldwide, harboring multi-faced monographs, 
whose pharmacologic potential albeit their therapeutic 
limits are well known. New formulations of conven-
tional cytotoxic drugs may open a door to a new qual-
ity of the pharmaceutical research. This redesign of 
“old fashioned” molecules to highly active pharma-
ceutical ingredients (API) could be a suitable practice 
capable of improve the therapeutic index [1-4]. In case 
of malignant brain tumors especially in the chemo-
therapy of glioblastoma multiforme (GBM) the anti 
cancer drug temozolomide (TMZ) 
(8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazin- 
4(3H)-one) has been well studied [5, 6]. It has been 
shown in recent phase III study, that a simultaneous 
therapy with TMZ improves survival rates for patients 
with GBM treated with radiotherapy [7]. Encouraging 
data [8] give reason to expand the intervention with 
TMZ to difficult tumor types like prostate cancer. Un-
der clinical conditions TMZ was absorbed rapidly into 
the blood, and spontaneously decomposed at physio-
logical pH to the cytotoxic methylating agent 
5-(3-methyltriazeno)-imidazole-4-carboxamide 
(MTIC). Its half-life and apparent oral systemic clear-
ance values were 1.8 hours and 97 ml/minute/m2, 
however neutropenia and thrombocytopenia limited 
the tolerable application doses to 1000 mg/m2. The 
cytotoxicity of TMZ appears to be elicited through 
adduction of methyl groups to O6 positions of guanine 
(O6mG) in genomic DNA [9] followed by recognition 
of this adduct by the mismatch repair system (MMR), 
which can mispair with thymine during the next cycle 
of DNA replication [10, 11].  Int. J. Med. Sci. 2008, 5 
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The half-life of TMZ [12] in plasma and the 
non-target-gene-specific alkylating mode of action can 
lead to undesired adverse reactions, which could result 
in discontinuation or interruption of therapy. TMZ 
therefore seems to be a good candidate for reformula-
tion, since our new TMZ derivatives could circumvent 
these problems by retaining the high efficiency but not 
the adverse effects of TMZ.  
The coupling of a peptide-based nuclear localiza-
tion sequence (NLS) leads to an active nuclear target-
ing minimizing the above described handicaps (Drug 
Design, Development and Therapy, in press). But due 
to their higher molecular mass and their phys-
ico-chemical characteristics the transport of TMZ-NLS 
peptide conjugates alone across the cellular membrane 
is poor. Therefore a transport molecule is needed so 
that a sufficient concentration of pharmacologically 
active molecules can reach their target side inside the 
nucleus. 
Our efforts resulted in suitable ligation modes of 
TMZ with a nuclear address peptide which in turn is 
connected to carrier molecules. For a better under-
standing a definition for “ligation” is given in chemis-
try the meaning of “ligation reaction” is the basis of the 
Diels-Alder chemistry, which we focus on here. 
Such a ligation reaction should meet the follow-
ing criteria: (1) rapid course of the reaction, (2) inde-
pendent from solvent properties, (3) no side reaction 
with other functional groups present in the molecules, 
(4) without additional coupling-reagents, (5) irreversi-
ble chemical reaction characteristics, and (6) an eco-
nomical procedure.  
Our concept is based on the ‘Click Chemistry’. It’s 
applications are increasingly found in all aspects of 
drug discovery, ranging from clue finding through 
combinatorial chemistry and target-templated in situ 
chemistry, to proteomics and DNA research, using 
Staudinger and Sharpless conjugation reactions 
[13-16]. In this regard the 1,3-dipolar cycloaddition 
developed by Huisgen has to be considered as a 'cream 
of the crop' [17]. 
Our ligation approach is based on cycloaddition 
reactions via the pericyclic Diels Alder Reaction (DAR) 
with ‘inverse-electron-demand’ (DARinv), which is a 
modification of π-electron-deficient N-heteroaromatics 
with electron-rich dienophils [18]. The DARinv is, in 
contrast to DAR, irreversible with the compounds we 
used. In this way the pharmaceutic TMZ was coupled 
to the modularly structured carrier. We called it 
TMZ-BioShuttle. During biological tests we reached a 
dramatically increased efficiency in two different tu-
mor cell lines in the glioblastoma cell line TP 366 and 
in the human prostate cancer cell line DU 145.  
The analyses of dilution series indicated for the 
application of the TMZ-BioShuttle that the spectra of 
the treatable tumor types could be extended.  
 
Materials and Methods 
Synthesis of the TMZ-derivative 
A 0.2 mol preparation with 42.7 mg 
4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,
9-trien-9-carboxylic acid chloride and 67.4 mg modi-
fied tetrazine as well as 28 µl triethylamine were dis-
solved in chloroform. The reaction process runs un-
disturbed and provides a defined product with the 
molecular weight (MW) m/e 513.  
Synthesis of the Boc-Lys(TCT)-OH 
42 mg cyclooctotetraen and 44 mg maleic acid 
anhydride were resolved in chloroform and methanol 
1 %. The chemical reaction is described by Reppe [19]. 
Solid phase peptide synthesis of the BioShuttle 
transporter 
For solid phase synthesis of the 
K(TCT)-NLS-S∩S-transmembrane transport peptide 
the Fmoc-strategy was employed in a fully automated 
multiple synthesizer (Syro II) [20]. The synthesis was 
carried out on a 0.05mmol Fmoc-Lys(Boc)-polystyrene 
resin 1% crosslinked and on a 0.053 mmol 
Fmoc-Cys(Trt)-polystyrene resin (1% crosslinked). As 
coupling agent 2-(1H-Benzotriazole-1-yl)-1,1,3,3- 
tetramethyluronium hexafluorophosphate (HBTU) 
was used. The last amino acid of the NLS-peptide was 
incorporated as Boc-Lys(TCT)-OH. Cleavage and de-
protection of the peptide resin were affected by treat-
ment with 90% trifluoroacetic acid, 5% ethanedithiol, 
2.5% thioanisole, 2.5% phenol (v/v/v/v) for 2.5 h at 
room temperature. The products were precipitated in 
ether. The crude material was purified by preparative 
HPLC on an Kromasil 300-5C18 reverse phase column 
(20 × 150 mm) using an eluent of 0.1% trifluoroacetic 
acid in water (A) and 60% acetonitrile in water (B). The 
peptides were eluted with a successive linear gradient 
of 25% B to 60% B in 40 min at a flow rate of 20 
ml/min. The fractions corresponding to the purified 
protein were lyophilized.  
Coupling of the transmembrane carrier - and the 
K(TCT)-NLS-Cys-module 
The K(TCT)-NLS-C and the transport peptide 
were oxidized in an aqueous solution of 2mg/ml in 
20% DMSO. After five hours the reaction was com-
plete. The oxidation progress was monitored by ana-
lytical C18 reversed-phase HPLC, and then the peptide 
was purified as described above. The purified material Int. J. Med. Sci. 2008, 5 
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was characterized with analytical HPLC and laser de-
sorption mass spectrometry in a Bruker Reflex II. 
Reagents and cell culture 
Human glioblastoma (GBM) primary cells (TP 
366) [21] and human prostate cancer cells (DU 145) [22] 
were provided by the DKFZ division of Biophysics of 
Macromolecules. All cell lines were cultured in DMEM 
(Gibco Cat. No. 12800) supplemented with 10% FCS 
and maintained in culture at 37°C with 5% CO2 at-
mosphere and 95% humidity.  
Chemotherapy treatment 
Pure temozolomide (TMZ) was purchased from 
Sigma-Aldrich, Germany (Cat. No. 76899) and the 
material was subdivided into two parts for subsequent 
processing. One part was followed up and coupled to 
the transporter molecules. As a control, the second part 
was dissolved in acetonitrile 10% (Sigma-Aldrich, 
Germany) with a final concentration of 0.2% acetoni-
trile. 
DU 145 and TP 366 cells were seeded (1 × 105 
cells/ml) in DMEM (control) and in DMEM containing 
a dilution series of TMZ and of TMZ-BioShuttle from 
50 to 6.25 µM respectively. The behavior of the cells 
was up to 6 days.   
Cell Cycle Analysis 
The effects on the cell cycle distribution were de-
termined by DNA flow cytometry. Flow cytometric 
analyses were performed using a PAS II flow cytome-
ter (Partec, Muenster, Germany) equipped with a 
mercury vapor lamp (100 W) and a filter combination 
for 2,4-diamidino-2-phenylindole (DAPI) stained sin-
gle cells. From native probes the cells were isolated 
with 2.1% citric acid/ 0.5% Tween 20 according to the 
method for high resolution DNA and cell cycle analy-
ses [23] at room temperature. Phosphate buffer (7.2g 
Na2HPO4 × 2H2O in 100ml H2O dest.) pH 8.0 contain-
ing DAPI for staining the cell suspension was per-
formed. Each histogram represents 30.000 cells for 
measuring DNA-index and cell cycle. For histogram 
analysis, we used the Multicycle program (Phoenix 
Flow Systems, San Diego, CA). 
 
Cell viability 
For detection of apoptotic cells and viability, a 
FACS Calibur flow cytometer (Becton Dickinson Cy-
tometry Systems, San Jose, CA) was used with filter 
combinations for propidium iodide. For analyses and 
calculations, the Cellquest program (Becton Dickinson 
Cytometry Systems, San Jose, CA) was carried out. 
Each histogram and dot plot represents 10.000 cells. 
After preparation according to Nicoletti [24] with 
modifications [25, 26], measurements were acquired in 
the logarithmic mode in Fl-3 and calculated by setting 
gates over the first three decades to detect apoptotic 
cells. Dead cells are positive for propidium iodide and 
stained red, living cells remain unstained. In the loga-
rithmic histogram the positions of unstained living 
cells in a are in the first 2 decades the 3th decade con-
tains cells with membrane damage, dead cells are 
placed in the 4th decade. 
 
Results 
Time-Course of Cell Growth and comet formation 
in DU 145 prostate cancer and TP 366 glioblastoma 
cells provoked by TMZ and TMZ-BioShuttle dilu-
tion series 
Two different cell lines originating from different 
tumor entities like the metastatic human prostate epi-
thelium adenocarcinoma, herein referred as DU 145 
(Figures 1-2) and TP 366 cells derived from human 
glioblastoma (Figures 3-4) were used to investigate the 
pharmacological effect of TMZ and TMZ-BioShuttle. 
To learn more about the DNA damage and cell 
death in the two different cell lines after treatment 
with TMZ as well as with TMZ-BioShuttle using the 
identical dilution series, we carried out comet assays in 
parallel probes (right columns of the figure 1 and 2). 
Basically the untreated cultures of DU 145 prostate 
cancer cells and TP 366 cells did not exhibit frag-
mented DNA. 
 
DU 145 Prostate cancer cells 
In order to determine the sensitivity of these cells 
we used a dilution series in a range from 50 to 6.25 µM 
of TMZ and TMZ-BioShuttle respectively.   
Two days after treatment with the TMZ final 
concentrations 6.25, 12.5 and 25 µM, the DU 145 cells 
s e e m e d  t o  b e  u n f a z e d  a n d  n o  v i s u a l  c h a n g e  i n  t h e  
phenotype could be observed under the light micro-
scope. Counting the corresponding cell numbers of-
fered a hardly detectable decrease of the cell number 
(from 1.15 to 1.05 × 106 cells) if anything compared to 
the untreated control with 1.12 × 106 cells. Only the 
probe treated with 25 µM TMZ revealed a decrease to 
0.844 × 106 cells (Figure 1). The comet assay study in-
dicated a higher sensitivity and exhibits fragmented 
DNA in the probes which were treated with 12.5, 25 
and 50 µM TMZ. The samples treated with 50 µM TMZ 
displayed a decrease of the cell number to 0.628 × 106. 
Additionally in the cell culture medium an increasing 
number of dead, clumped DU 145 cells could be ob-
served. 
 Int. J. Med. Sci. 2008, 5 
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Figure 1  Microscopical monitoring of the human prostate 
cancer DU 145 cells 2 days after treatment with TMZ. In the 
comet column the scale bar represents 20 µm. The microscopic 
pictures were taken in phase-contrast, enlargement 200×. 
TP 366 glioblastoma cells 
Light microscopical studies showed a reduced 
cell population after treatment with 6.25 µM TMZ for 6 
days which was increased further diminished under 
two fold application doses (12.5; 25 µM) from 6.2 × 105 
cells (untreated control) to 5.3; 4.8, and 2.1 × 105 cells. In 
the TP 366 cells the TMZ probe treated with 50 µM, 
however, the cell population remained at the level of 
the 25 µM treated cells (2.1 × 105 cells) and may reach a 
saturation level. 
After 6 days treatment with 6.25 µM TMZ (figure 
1 and 2) the TP 366 cells showed differently sized and 
fragmented dead cells, sporadic comet structures and 
shrunken nuclei. In relation to the increased applica-
tion doses an increase of fractionated DNA and shrunk 
nuclei could be observed. The TP 366 probe treated 
with 50 µM TMZ exhibited sporadic comets and al-
most condensed nuclei. The probes treated with 
TMZ-BioShuttle displayed a deviant behavior. The 
6.25 µM TMZ-BioShuttle treated cells offer no DNA 
fragmentation, but their nuclei seemed to be partly 
swollen and diminished (figure 2). The latter fraction 
was increasing in accordance to the increased applica-
tion doses. In addition the total cell count of the TMZ 
treated samples was lower, compared to the cell 
number in the control and cells treated with 
TMZ-BioShuttle. 
The comet assay study detected no DNA frag-
mentation in the untreated control TP 366 cells until 
144 hours. After application of TMZ-BioShuttle (6.25 
µM) and more, much more DNA-fragments could be 
observed (figure 4). Indeed the use of higher applica-
tion doses enhanced DNA fragmentations and the ra-
tios of shrunk nuclei of TP 366 (figure 4 right column). 
 
 
 
 
 
 
Figure 2  Microscopical monitoring of the human prostate 
cancer DU 145 cells 2 days after treatment with 
TMZ-BioShuttle. In the comet column, the scale bars in the 
maps represent 20 µm. The microscopic pictures were taken in 
phase-contrast, enlargement 200×. Int. J. Med. Sci. 2008, 5 
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Figure 3  Microscopic and comet assay studies of untreated 
TP 366 cells and treated with various concentrations of TMZ; 
the scale bar represents 20µm.  
Cell Cycle Studies 
Here we present measurements of the cell activi-
ties like the cell cycle analysis using the flow cytomet-
ric method and a calculation of the percentage of cells 
in different phases of the cell cycle. These data were 
obtained after treatment with TMZ and the 
TMZ-BioShuttle in depency on the application dose. 
We determined the cell cycle behaviour of TP 366 
glioma cells and DU 145 prostate cancer cells. To in-
vestigate the influence of TMZ with and without 
BioShuttle transporter we performed a dose-response 
analysis of the cell cycle shown in Figures 5 and 6.  
TP 366 glioblastoma cells treated by TMZ and 
TMZ-BioShuttle dilution series 
Figure 5 exhibits the cell cycle distribution of TP 
366 cells 6 days after treatment with increasing con-
centrations of TMZ and TMZ-BioShuttle is shown in 
f i g u r e  5 .  T h e  c e l l  c y c l e  d i s t r i b u t i o n  i s  s i g n e d  a s  G 1  
phase, S phase and the G2/M phase. These cells show 
a diploid cycle (red coloured). The plot of the un-
treated control is demonstrated (figure 2, line 1) and 
exhibits a G1 cell fraction of 86.4 % and a G2 cell frac-
tion 5.7 %. Looking the TMZ treated cells the contin-
gent of cells in the S phase amounts to 7.8 %. In com-
parison to the S phase fraction of untreated control the 
percentage of S phase cells treated with 6.25 µM TMZ 
is increased to 11.1 %. The doubling of the TMZ dose to 
12.5 µM results in a slightly decrease of the S phase 
fraction to 9.4 %. The further increase of the TMZ 
concentration to 25 µM and 50 µM has barely influ-
enced the amount of the cells in the S phase with 9.1 % 
and 9.8 % respectively. Regarding the G2 phase we 
observed a dose dependent linear increase of the cell 
ratio. A concentration of 6.25 µM depicted an increase 
of cells from 5.7 % (control) to 10.2 %. The TMZ dose of 
12.5 µM results in a scarcely increase to 10.7 %, but the 
doubling of the TMZ concentration to 25 µM and fur-
ther to 50 µM resulted in an intense increase of the cell 
fraction in the G2/M phase with 15.9 % and 21.3 % 
respectively. The analysis of the dose dependent effect 
on the G1 phase exhibited the following trend: the 
starting dose rate was 6.25 µM TMZ, doubling of the 
doses to 25 and to 50 µM showed a reciprocal propor-
tionality to the percentage of G1 cells, 74.8% and 68.8% 
(figure 2, right column).  
 
 
Figure 4  Microscopic and comet assay of untreated TP 366 
glioblastoma cells, and 6 days after treatment with 
TMZ-BioShuttle; the scale bar represents 20µm. Microscopic 
magnification is 200-fold in the phase contrast microscope.  Int. J. Med. Sci. 2008, 5 
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The TMZ-BioShuttle treated TP 366 cells pre-
sented a cell cycle behaviour strongly differing from 
the untreated control and from the TMZ treated cells. 
The probe treated with 6.25 µM evidenced a re-
duced cell fraction in G1 phase of 70.6% already. The 
TP366 cells treated with doses 12.5 and 25 µM indicate 
G1 ratios of 57.9 and 37.6% respectively. Especially the 
data of the G2/M phase are demonstrative. From 6.25 
µM up to 25 µM we observed an increase of the ratio of 
cells in G2/M from 19.1 %, via 28.6 % to 37.6 %. In 
comparison with the corresponding TMZ data, we 
found a continuous G2/M enhancement with the fac-
tor 2 starting at 6.25 µM! to 25 µM and a factor 3 in the 
probes treated with 12.5 µM.  
Due to the high amount of 
dead cells the estimation of the 
cell cycle distribution in TP 366 cells treated with 50 
µM TMZ-BioShuttle was difficult to perform and to 
analyse. It shows an increase of the cell fraction in the 
G1 phase to 68.8% which is identical to the corre-
sponding probe treated with TMZ. Consistently in-
creased amounts of the S phase cells could be detected 
compared to both the S phase in the control and the 
corresponding probes treated with TMZ. The trend of 
G2/M phase cells turned to the opposite direction. In 
the S phase not definitive trend arose from the applied 
dose.  
 
Figure 5  The cell cycle distribution 
in TP 366 glioblastoma cells dependent 
on the applied concentration of TMZ 
(right column) and TMZ-BioShuttle 
(left column) 6 days after treatment. 
The axes of coordinates represent the 
cell number; the abscissae represent the 
corresponding DNA content. The left 
peak depicts the amount of cells in the 
G1 phase; the area of the right peak 
describes the ratio of cells in the G2/M 
phase. The area between both peaks 
displays the amount of the cell fraction 
residing in the S phase. The insert de-
scribes the percentage of cells in the 
phases of the cell cycle. Int. J. Med. Sci. 2008, 5 
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Figure 6  The cell cycle ratio of DU 145 prostate cancer cells dependent on the applied concentration of TMZ (right column) and 
TMZ-BioShuttle (left column) 2 days after treatment. The axes of coordinates represent the cell number; the abscissae represent the 
corresponding DNA content. The left peak depicts the amount of cells in the G1 phase; the area of the right peak describes the ratio 
of cells in the G2/M phase. The area between both peaks displays the amount of the cell fraction residing in the S phase. 
 Int. J. Med. Sci. 2008, 5 
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Cell cycle behaviour of DU 145 cells after treatment 
with TMZ and TMZ-BioShuttle dilution series 
At a first glance the histograms reveal a lower 
sensitivity of DU 145 prostate cells against TMZ 
treatment compared to the results of TP 366 cells. The 
untreated DU 145 control exhibits a cell cycle distribu-
tion as follows: G1 – 58.5%; S phase – 29.8% and G2/M 
phase 11.6%. The ratio of TMZ treated cells in the 
G2/M phase amounts to 12.8%; 15.4% and 23.5% and 
is constantly increasing in correlation to the applica-
tion doses of 6.25; 12.5 and 25 µM.  
The percentage of the S phase cells after treatment 
with the above described concentrations were almost 
constant 29.5% and close to the control. The cells in the 
G1 fractions treated with increasing concentrations up 
to 25 µM of TMZ presented a moderate but uniform, 
continuous decrease from 58.5% (control), via 57.5%, 
56.4%, to 48.6 % and then a strong decline to 29.8%. 
The DU 145 probe treated with 50 µM TMZ showed 
22.3% G2/M phase cells and a dramatic increase of the 
S phase cell fraction to 47.7%. 
The DU 145 cells treated with the TMZ-BioShuttle 
under identical conditions offered a cell cycle behav-
iour which strongly differs from the TMZ probes. The 
percentage of cell fractions in G1 phase seemed to be 
nearly constant 58.5% comparing the untreated control 
versus the treated cells with concentrations 6.25µM 
59.2 %and 12.5 µM 57.4%. The concentrations of 25 and 
50 µM gave rise to a marked decrease of the percentage 
of cells from 45.5% to 20.7% in G1 which corresponds 
to one-third of the related TMZ treated probe! 
The relative amounts of S phase cells in the con-
centration series with increasing TMZ-BioShuttle 
doses of 6.25, 12.5, 25, and 50 µM offered a reciprocal 
proportionality and showed a small but continuous 
decrease of cell number from 29.8% (control), via 
28.8%, 28.1%, 27.1%, to 24.2% respectively. It is im-
portant to note that the latter result showed a strong 
reduction comparing 47.7% (TMZ) to 24.2% 
(TMZ-BioShuttle) which equates a degression of 50%. 
The concentration series with increasing amounts of 
TMZ-BioShuttle indicated a direct concentration de-
pendence and displayed a moderate increase of the cell 
number of DU 145 cells in the G2/M fraction from 
11.6% (control) to 11.9% in the 6.25 µM probe via 12.5, 
25 to 50 µM. A strong rise of the S phase cells from 
14.6% via 27.4% to 55.1% was shown. Doubling the 
applied dose increased cell number in the G2/M phase 
mote than 100%! Additionally, the direct comparison 
of the probe treated with 50 µM TMZ-BioShuttle with 
the corresponding TMZ probe of DU 145 cells showed 
a dramatic increase in the percentage of cells in the 
G2/M phase (from 22.3% to 55.1%), revealing a G2/M 
block. 
 
Figure 7  The dose dependent effects of TMZ (C/D) as well as TMZ-BioShuttle (A/B) in the cell cycle behaviour of TP366 
glioma (A/C) and DU 145 prostate cancer (B/D) cells. ♦ G1phase;  S phase; S G2/M phase Int. J. Med. Sci. 2008, 5 
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Discussion 
The number of old-fashioned cytotoxic drugs, 
whose effectiveness is well understood, is multi-faced. 
However, if highly effective substances do not reach 
their target site after application, what is their benefit? 
Therefore questions about the bioavailability remain to 
be answered, whereby the concentration in the blood-
stream is not meant here, but rather the concentration 
directly at the site of pharmacological action, like the 
genomic DNA in tumor cell nuclei.  
A substantial progress in the drug development 
will be achieved by improvement of the delivery and 
subcellular targeting of the drug as yet unappreciated 
and meaningless.  
The BioShuttle delivery and targeting platform, 
facilitating the transport of DNA derivatives into liv-
ing cells was described [27, 28] as well as transport of 
diagnostics into the cytoplasm and nuclei of tumor 
tissues [29, 30]. There is no doubt that constructs like 
the TMZ-BioShuttle, as an example, could play a 
helpful role in the treatment of cancer. The design of 
such shuttles needs to incorporate features that reduce 
undesired adverse reactions but maintains the efficacy.   
We selected the highly efficient chemotherapeutic 
TMZ as a qualified candidate, since encouraging re-
sults in treatment of in brain tumors [31] remain un-
endorsed in the treatment of hormone-refractory 
prostate cancer (HRPC) [32].  
Parallel sets of experiments with TP 366 glioma 
cells and DU 145 prostate cancer cells were carried out 
and confirmed a lesser sensitivity of DU 145 prostate 
cancer cells against TMZ treatment. Whereas the TP 
366 cells showed an increased DNA damage after TMZ 
treatment up to a final concentration of 6.25 µM, the 
DU 145 cells exhibited very few DNA damage meas-
ured by comet assay. The increase of the application 
dose however did not induce an increased number of 
comets (figure 1). This phenomenon was already 
documented in studies with ceramide-induced cell 
death [33].   
In DU 145 cells we compared the dose-dependent 
application of TMZ and TMZ-BioShuttle of seeded 
versus harvested cells after 48 hours. In comparison to 
the control (1.12) a linear inverse proportionality (1.15; 
1.05; 0.844; and 0.628) to the dilution series of 6.25; 12.5; 
25; and 50 µM TMZ was demonstrated.  
These data permit to assume a minimum of TMZ 
application dose between 25 and 12.5 µM. Dilution 
s e r i e s  w i t h  5 0  µ M  t o  6 . 2 5  µ M  o f  T M Z - B i o S h u t t l e  
showed an increase of shrunk nuclei (figures 2 and 4). 
The TMZ-BioShuttle revealed the identical subthresh-
old in DU 145 cells but the quotient 0.414 at 50 µM 
suggests a higher pharmacological potential.  
The results achieved with both cell lines (TP 366 
and DU 145) treated with the TMZ-BioShuttle differ in 
the expected augmentation of DNA comets: All cells 
were visibly swollen, but we could not detect an in-
creased number of comets. This suggests a deconden-
sation of chromatin in the nuclei. This happens when 
chromosomes are exposed to DNA replication inhibi-
tion caused by failure to constitute compact chromatin 
areas during mitosis [34]. It could be explained with 
the involvement of the transcription of genes express-
ing histone regulating proteins responsible for forma-
tion of the chromatin structure and for the compact 
package of DNA [35].  
We investigated the cell cycle of TP366 after 
treatment of the glioblastoma cells with TMZ. It inter-
fered with the cell cycle and exhibited a decreased 
number of cells in the S phase fraction as shown 144 
hours after TMZ-application when a contingent of the 
S phase cells of 8% was detectable. 
The phenomenon of a reduced S phase (8% ver-
sus control 11%) in the TMZ treated TP 366 cells is not 
contradictory to the common effects of alkylating 
agents which cause a retardation of the rate of cell di-
vision [36]. A possible explanation for the strongly 
decreased S phase cell number in the TMZ-BioShuttle 
treated probes would be the existence of a S phase cell 
cycle arrest as documented in a bimodal TMZ/ inter-
feron-β (IFN-β) study [37]. Our flow cytometry ex-
periments also displayed a strong cell cycle arrest in 
the S phase [38]. An interesting criterion for a pro-
longed late S/G2 phase suggests the implication of the 
histone acetyltransferase 1 (HAT1) which participates 
in recovering block-mediated DNA damages [39].  
The fact that the glioblastoma cells arrest in the 
G2/M phase after TMZ-treatment was documented by 
Hirose et al. [40] and could be confirmed with the TP 
366 cells. Moreover the treatment with TMZ-BioShuttle 
resulted in a clearly increased G2/M phase of 72%. It 
seems to be attributed to interactions of TMZ and 
TMZ-BioShuttle with the mitogen-activated protein 
(MAP) kinase p38α, which is activated by the mis-
match repair system (MMR) and is responsible for the 
TMZ-induced G2/M block [40].  
After cell exposure to the TMZ-BioShuttle for 144 
hours, the observed strong increase of the G2  phase 
cells of TP 366 cells possibly originate from the already 
documented inhibition of the RNA and protein syn-
theses, which are necessary for the successful comple-
tion of G2 and the initiation of mitosis. These 
G2-arrested cells were found to be deficient in certain 
proteins that may be specific for the G2-mitotic transi-Int. J. Med. Sci. 2008, 5 
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tion [41]. The obstruction of the cell cycle process is 
caused by the stop of this transition and results in the 
decrease of the G1 phase cell fraction (26%) of the 
TMZ-BioShuttle treated TP 366 cells which appear to 
be consequence of their disability passing in the mi-
totic process. 
A sensitivity of DU 145 and TP 366 cells against 
TMZ and a dramatically increased sensibility against 
TMZ-BioShuttle is shown in figure 4. The present data 
document a different cellular contumaciousness to 
TMZ treatment. A real effectiveness of the pure TMZ 
in DU 145 cells could not be observed, whereas in 
contrast clear cell killing effects, caused by 
TMZ-BioShuttle, were detected.  
It is important to note that the TMZ-BioShuttle 
treatment of DU 145 and the TP 366 cells redounds to 
cell killing effects as shown in figure 4.  
As a general rule the different sensitivity of tumor 
cells against chemotherapeutics is dependent on mul-
tiple mechanisms like multiple drug resistance sys-
tems. The relative low sensitivity of DU 145 prostate 
cancer cells after treatment with TMZ is evident, and 
the disappointing results of TMZ trials of prostate 
cancer can be explained by the increased 
O6-methylguanine-DNA methyltransferase (MGMT) 
repair activity. DU 145 cells show an increased MGMT 
activity [42], associated with the decrease of the 
pharmacologic effect after alkylating with TMZ alone. 
The increased MGMT expression and activity corre-
lates with the malignant phenotype [43]. We regard the 
potential utility of this epigenetic alteration as an ap-
propriate biomarker for prostate cancer [44] and an 
important prognostic feature for the clinical outcome 
in glioblastoma [45]. The fact that die blood brain bar-
rier (BBB) no presents an hurdle for TMZ could explain 
the higher pharmacological effects of TMZ in glioma 
cells. It is important in so far that the delivery and the 
targeting of active substances play a decisive role and 
must be further scrutinized. The TMZ-BioShuttle could 
be an appropriate candidate.   
The physico-chemical properties of TMZ which 
have an impact on its bioavailability limit its pharma-
cological effectiveness. Despite the benefit of the con-
comitant treatment with radiotherapy plus TMZ, he-
matologic toxic effects in patients treated with TMZ 
are documented in multicenter studies by Stupp [46]. 
A TMZ-derivatization with targeting transporters 
molecules and subcellular address components holds 
tremendous potential to optimize treatment of dis-
eases. Enhanced cellular delivery and active transport 
of TMZ into the cell nuclei as site of pharmacological 
action permit to expect lower application doses with 
concomitantly decreased limiting side-effects.   
Our shuttle, designed for facilitating the rapid 
transport across cellular membranes, improved their 
own delivery and their own targeting under per-
petuation of the pharmacological activity in cells and 
tissues while protecting cells in the bloodstream by 
omission of undesired side-effects like:  
Strong suppression of the peripheral lympho-
cytes result in discontinuation of therapy and prob-
lems associated with systemic drug administrations, 
which are:   
•  even biodistribution of pharmaceuticals through-
out the body;  
•  the lack of drug specific affinity toward a patho-
logical site;  
•  the necessity of a large total dose of a drug to 
achieve high local concentration;  
•  non-specific toxicity and strong adverse 
side-effects due to high drug doses [47, 48].  
The application of the TMZ-BioShuttle could 
minimize the handicap of TMZ on the therapy of pa-
tients with brain tumors but the establishment of the 
TMZ-BioShuttle necessitates new ways for the synthe-
sis. Conditions which hampered the above postulated 
criteria like rapid and whole concurrent chemical re-
actions in aqueous solution at room temperature for a 
proper chemical ligation of functional peptides could 
be circumvented using the ‘inverse-electron-demand’ 
of the Diels Alder Reaction.  
Thus, TMZ-BioShuttle has been reformulated to 
decrease the toxic features in normal cells but retain 
the pharmacologic behavior in target cells; this was 
achieved as follows: coupling the amide group of the 
TMZ with a tetrazine which acts as dien-component 
and connects the NLS module with the tridecadien 
(TCT) component operating as dienophil.  
The presented publication shows that a proper 
chemistry contributes to the optimization of the 
pharmacological properties of the already efficient 
pharmaceutics like TMZ.  
The novel properties of the TMZ-BioShuttle could 
give reason to the extension to tumor types like pros-
tate cancer, especially in hormone refractory situa-
tions.  
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